Abstract
BackgroundThe relationship between the uptake of [18F]fluoroerythronitroimidazole ([18F]FETNIM), blood flow ([15O]H2O) and 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) and immunohistochemically determined biomarkers was evaluated in squamous-cell carcinomas of the head and neck (HNSCC).Methods[18F]FETNIM and [18F]FDG PET were performed on separate days on 15 untreated patients with HNSCC. Hypoxia imaging with [18F]FETNIM was coupled with measurement of tumor blood flow using [15O]H2O. Uptake of [18F]FETNIM was measured as tumor-to-plasma ratio (T/P) and fractional hypoxic volume (FHV), and that of [18F]FDG as standardized uptake value (SUV) and the metabolically active tumor volume (TV). Tumor biopsies were cut and stained for GLUT-1, Ki-67, p53, CD68, HIF-1α, VEGFsc-152, CD31 and apoptosis. The expression of biomarkers was correlated to PET findings and patient outcome.ResultsNone of the PET parameters depicting hypoxia and metabolism correlated with the expression of the biomarkers on a continuous scale. When PET parameters were divided into two groups according to median values, a significant association was detected between [18F]FDG SUV and p53 expression (p =0.029) using median SUV as the cut-off. There was a significant association between tumor volume and the amount of apoptotic cells (p =0.029). The intensity of VEGF stained cells was associated with [18F]FDG SUV (p =0.036). Patient outcome was associated with tumor macrophage content (p =0.050), but not with the other biomarkers. HIF-1α correlated with GLUT-1 (rs =0.553, p =0.040) and Ki-67 with HIF-1α (rs =506, p =0.065). p53 correlated inversely with GLUT-1 (rs = −618, p =0.019) and apoptosis with Ki-67 (rs = −638, p =0.014).ConclusionsA high uptake of [18F]FDG expressed as SUV is linked to an aggressive HNSCC phenotype: the rate of apoptosis is low and the expressions of p53 and VEGF are high. None of the studied biomarkers correlated with perfusion and hypoxia as evaluated with [15O]H2O-PET and [18F]FETNIM-PET. Increased tumor metabolism evaluated with PET may thus signify an aggressive phenotype, which should be taken into account in the management of HNSCC.
Highlights
The relationship between the uptake of [18F]fluoroerythronitroimidazole ([18F]FETNIM), blood flow ([15O]H2O) and 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) and immunohistochemically determined biomarkers was evaluated in squamous-cell carcinomas of the head and neck (HNSCC)
In the absence of oxygen, HIF-1α binds to hypoxia-response elements (HREs), thereby activating the expression of numerous hypoxia-response genes such as those involved in angiogenesis, glycolysis and oxygen delivery
We have previously described the pharmacokinetic properties of [18F]FETNIM as a hypoxia tracer in experimental tumors [13,14] and in patients with squamous-cell carcinoma of the head and neck (HNSCC) [12,15,16]. [18F] FETNIM PET studies in patients with HNSCC were combined with blood flow measurements utilizing [15O]H2O and [18F]FDG
Summary
The relationship between the uptake of [18F]fluoroerythronitroimidazole ([18F]FETNIM), blood flow ([15O]H2O) and 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) and immunohistochemically determined biomarkers was evaluated in squamous-cell carcinomas of the head and neck (HNSCC). Tumor blood flow is variable causing irregular metabolic gradients, gradients in the oxygen and glucose concentrations [1]. One could say that the cellular response to hypoxia is intended to prevent cell death and an increased level of intracellular HIF-1α has been associated with a poor prognosis and resistance to therapy in cancer [3]. In addition to the fact that hypoxia upregulates glycolysis, classical biochemical studies have shown high rates of glycolysis in cancer cells, independent of the presence of oxygen (Warburg’s effect) [4]. In addition to elevated glycolysis, tumors often show an increased expression of glucose transporters and/or hexokinase activity in comparison to normal tissues
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have